Financing the Evolution
Executive SummaryThe drug industry needs to evolve a new financing system in order to pay for R&D expenses that will almost of necessity rise faster than sales. A few companies are pointing the way, with deals that allow them to tap into other companies' and investors' funding resources.
You may also be interested in...
The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date.
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.
No device-related warning letters were released by the US FDA the week of 10 December.